[Prospective observational study of outpatients with schizophrenia in Poland: preliminary 6 month efficacy and tolerability results].
To compare the effectiveness and tolerability of olanzapine and other antipsychotic treatments (6 months after enrollment) in Polish patients with schizophrenia participating in the IC-SOHO (the Intercontinental Schizophrenia Outpatient Health Outcomes) study. IC-SOHO is a 3-year, global, prospective, observational study examining health outcomes in outpatients with schizophrenia undergoing treatment with antipsychotics. Patients were offered enrollment by a psychiatrist if they initiated or changed antipsychotic medication for the treatment of schizophrenia. The study was designed to provide two patient cohorts of approximately equal size: patients who initiated or switched to olanzapine, and patients who initiated or switched to non-olanzapine antipsychotic therapy. Mean changes in positive, negative, cognitive, depressive and overall symptoms from baseline to 6 months, as measured using the CGI scale, were assessed. The incidence of extrapyramidal symptoms and sexual dysfunctions and weight changes were compared. Out of 7648 patients participating in the IC-SOHO study, 626 patients were enrolled in Poland. After 3 and 6 months of treatment, significantly greater improvement in overall symptoms measured using the CGI scale was observed in patients with olanzapine than in those with other antipsychotics. Response rate at 6 months was significantly higher in the olanzapine group than in the non-olanzapine group. Incidence of extrapyramidal symptoms and sexual dysfunctions was lower in olanzapine group. After 6 months, olanzapine-treated patients showed greater improvement of clinical status compared with other antipsychotic treatment. Olanzapine treatment was more beneficial for patients; comparing to other antipsychotic treatment less extrapyramidal symptoms and sexual dysfunctions were observed.